Aileron Therapeutics, Inc.
NASDAQ: ALRN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Brian Windsor
- Employees
- 15
- Headquarters
- Boston, United States
- IPO year
- 2017
- Market cap
- $45.7M
- Website
- https://www.aileronrx.com
Loading ALRN…
Loading profile data…Frequently asked questions about ALRN
What does Aileron Therapeutics, Inc. (ALRN) do?
Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting periphera...
Where does ALRN trade?
Aileron Therapeutics, Inc. (ALRN) trades on the NASDAQ Capital Market.
What sector is ALRN in?
Aileron Therapeutics, Inc. (ALRN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aileron Therapeutics, Inc.?
James Brian Windsor is the chief executive officer of Aileron Therapeutics, Inc. (ALRN).
Where is Aileron Therapeutics, Inc. headquartered?
Aileron Therapeutics, Inc. is headquartered in United States.
Does ALRN pay a dividend?
Aileron Therapeutics, Inc. (ALRN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALRN go public?
Aileron Therapeutics, Inc. (ALRN) completed its initial public offering in 2017.